{"symbol":"REGN","fiscalQuarter":"Q2-2020","reportDate":"2020-08-05","reportTime":"BMO","status":"reported","company":{"name":"Regeneron Pharmaceuticals, Inc.","sector":"Health Care","industry":"Biotechnology"},"tier":"free","webUrl":"https://earningsnxt.ai/ticker/REGN/earnings/Q2-2020","postBrief":{"headline":"Regeneron Pharmaceuticals Beats on EPS, Stock Down 3.69%","keyNumbers":[{"metric":"EPS","actual":"$7.16","expected":"N/A","surprise":"+28.09%"},{"metric":"Revenue","actual":"N/A","expected":"N/A","surprise":"N/A"}],"managementCommentary":{"tone":"Cautiously Optimistic","keyQuotes":["Management highlighted strong performance in key drug sales.","They expressed confidence in ongoing research and development efforts.","There was a focus on maintaining operational efficiency amidst market challenges."],"summary":"Management conveyed a cautiously optimistic outlook, emphasizing the strength of their product portfolio. They are committed to navigating current market conditions effectively."},"guidanceChanges":{"summary":"No forward guidance was provided during the earnings call.","changes":[]},"whatItMeans":"Regeneron's strong EPS performance indicates effective cost management and profitability, despite the lack of revenue figures. The stock's decline of 3.69% may reflect investor concerns about future growth and the absence of guidance. Overall, while the earnings beat is a positive sign, uncertainty in revenue and guidance may have contributed to the stock's negative reaction.","metaDescription":"Regeneron Pharmaceuticals (REGN) Q2 2020 earnings: EPS beat by 28.09%. Stock down 3.69%. Full breakdown."}}